Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Funny. You and I were walking the identical path the past 5 minutes. You here and me, on another board. The observation is simple to any who might look. GLTA(Longs). It is going to be a fun week/month.
10 previous. Most recent 5/14/2013. EDGAR.gov is very simple to use.
Of course it can be applied, as tea leaves and tarot can describe the future.
As for spike in share price, there are a number of scenarios that could result in share price spike. Buy out is one. I am prepared for a number of outcomes, not all positive. I am, however, betting on positive.
GLTA(Longs)
Genius breaks the mold.
“M&A for Idiots” is a book whose readers are aptly described in its title.
GLTA(Longs)
Waiting beyond open will be like throwing money out the window. If there are buyers poised they best jump.
etiotropic (e?te-o-trop'ik) [Gr. aita, cause, + tropos, turning]
Directed against the cause of a disease; used of a drug or treatment that destroys or inactivates the causal agent of a disease. Opposite of nosotropic.
Medical Dictionary, © 2009 Farlex and Partners
RBL findings detail Brilacidin’s direct intervening and disruption of the viral membrane.
A new type of drug. That’s another way of saying first-in-class which has often been the phase used to describe Brilacidin. The timing of the cited article seems a touch early. But it does appear well after the peer review article was written.
Ya gotta love the global intrigue. Like a movie script. ‘’Cept this time I’m getting paid to watch.
The NT 10-Q is more verbose than required to satisfy the SEC filing requirement.
A very interesting NT 10-Q.
https://www.sec.gov/Archives/edgar/data/1355250/000147793221000911/ipix_nt10q.htm
Consider the date range to be reported in this 10-Q. A period of preparation and planning. Set-up not knock-out. The commentary, the anticipation, being created is a bit on the frothy side. This 10-Q may very well be cut and dry boredom. I'd like revelations but I would not invest too much hope in the bounty of a quarterly report.
Bulls are looking for a KO. Be wary of the counter punch that will land if the 10-Q fails to deliver the 10-count blow. Solid footwork wins championship belts.
GLTA(Longs)
Exactly. And then in a moment of criminal mastermind brilliance he instantiated a Ph II Clinical Trial to expose the Brilacidin fraud. Ultimate self-own. The Casey Jones of CEOs derails his own gravy train.
Up or Down. Innovation Pharmaceuticals, DeGrado and Leo, put Brilacidin to the test. The definition of, “put your money where your mouth is”. Quite simply, an act of courage.
GLTA(Longs)
COVID-19 waning in 2021? Perhaps so, hopefully so. Financial Analysts who pin their names and reputation to the top of their commentary still see 2021 as a COVID-driven money maker. https://apple.news/A_6AjljgdQu6AM-_JhtbaBA
Maybe Brilacidin, through EUA gets a piece of the market.
Maybe COVID-19, through mutations, roars back.
Maybe BP, through foresight, recognizes the pan-Corona antiviral potential of Brilacidin and buys ahead of the next lethal zoonotic killer.
Maybe the US, Europe, China, uncharacteristically, buy first-in-class Brilacidin to stockpile as a GDP-saver insurance policy.
In any case we won’t have long to wait. The efficacy of Brilacidin will be known by all before Spring gives way to Summer.
GLTA(Longs)
Also available on Reddit IPIX community. The more investors know the more they will know Brilacidin is the real thing.
Spot on. I’ll stick to my $5billion valuation for Brilacidin-COVID
Think about the market Brilacidin will enter. Now consider, how many of the existing treatments possess pan-Corona potential. COVID19 isn’t the first corona virus and it won’t be the last.
Biopharma Companies With COVID-19 Treatments See $10 Billion Market in 2021 - Morningstar
https://apple.news/A_6AjljgdQu6AM-_JhtbaBA
Terrific reply and info. Thank you.
This is understood and I appreciate the restatement. Fast Track certainly provides for greater and more frequent engagement between Pharma and FDA.
I’d like the poster to substantiate the assertion that the FDA is discouraging IPIX from delivering PRs. Had the poster cited SEC concerns I would not have been taken aback. But I can’t see the FDA giving a rat’s ass if Leo were to PR step by step trial progress.
If the FDA has placed restrictions on shareholder communications that to me is news and is disconcerting.
Non-confrontational question.
What evidence (link or published excerpt), can you provide to substantiate the assertion made in the middle two paragraphs?
It means Shorts are grasping at straws.
GLTA(Longs)
I agree with other replies you have received. The FDA will not seriously consider emergency use of B-COVID before (and assuming), positive results in the planned Phase 2 trial.
For background and links to regulatory guidelines consider reviewing Innovation Pharmaceuticals Expanded Access page.
http://www.ipharminc.com/expanded-access-and-compassionate-use
I answered your Reddit question. I’ll leave it to you to decide if it has value.
It is on Reddit: https://www.reddit.com/r/IPIX/
I don’t see that in my search. Provide a link, please.
Written elsewhere in Reply to a newly minted Innovation Pharmaceuticals investor.
The success of Brilacidin in coming weeks and growing investor awareness of Innovation Pharmaceuticals in coming weeks and months will be very good for a very small community of investors. The impact of Brilacidin on the pandemic, the lives saved and suffering ameliorated will benefit millions. This is not a hyperbolic statement. The revolutionary design, the mimicry of nature’s own defensive protein structures, will usher in a new era of antiviral, antibiotic medicine. Innovation Pharmaceuticals and Dr. William DeGrado will be household names. (Sorry Leo, your heroics will go largely unnoticed outside the investor bubble.)
Also noted in the article (https://res.mdpi.com/d_attachment/viruses/viruses-13-00271/article_deploy/viruses-13-00271.pdf page 10), that synergies have been evaluated with favipiravir. Favipiravir noted on this board yesterday as a Euro SOC.
For those in the medical community who might worry about modifying standard of care from R (better than nothing), to Brilacidin (excellent test results but new and unknown), they can opt to keep R in play while adding a Brilacidin regimen to the existing treatment protocol.
$5billion.
Thank you.
Mitcheroo and Petermax- with your permission(s), may I post to Reddit- IPIX?
All (many, many) locked.
I learned a difficult lesson investing in JAZZ. I owned shares in 2009-2010 or thereabouts. I was new to pharma stocks, vulnerable to misinformation and unaccustomed to the rollercoaster that is emerging-pharmaceutical investing. I sold at a small loss. Chalked it up to experience and moved on. Sometimes getting out quick and limiting your losses is a smart move. But winning and losing stocks often follow a similar sp pattern at startup. What JAZZ taught me is to do my DD. Follow public announcements and filings. Treat chat board expertise with heavy doses of salt. Be patient. And once you’ve defined and acquired your position hold tight. There is a difference between pain and injury. If one’s DD is good then stay the course through clinical trials. (Where truth is revealed for investors and inventors)
GLTA (Longs), the moment of truth has arrived.
Take a look at this Change.org petition for Hedge Fund transparency.
https://www.change.org/p/u-s-securities-and-exchange-commission-sec-retail-investors-demand-market-transparency-please-sec-amend-form-13f-requirements
If you think it might appeal to the WallStreetBets crowd please promote it to that community.
Submitted:
In war time individuals and companies deemed to profited at the expense of lives were prosecuted. Emerging pharmaceutical firms are frequently targeted by speculators, Shorters, who manipulate share prices in order to gain profit while delaying development of life saving drugs. A prime example; Innovation Pharmaceuticals has a RBL-Tested, SI-400+ anti-viral COVID-19 candidate Fast Tracked and Phase-2 Test approved by the FDA, but struggles to secure funding to run clinical trials. It’s criminal. Yet the SEC and the Justice Department permit rampant, predatory stock manipulation while lives are lost. What will a Biden Administration do to support emerging pharmaceutical companies to get desperately needed therapeutics into clinical testing and into hospitals to save lives?
Many a good man has died with live rounds in the chamber.
I considered this particular statement carefully when the PR came out. The structure and word choice is purposeful.
There was some consternation on the board, at the time of release, that IPIX had wait and was only just finalizing with testing sites. By my reading I don’t believe there was need for alarm or complaint. The key phrase in the sentence is “...contracts to add additional clinical sites...”. I imagine that there were a number of testing locations willing, able and cost effective for IPIX to negotiate and execute test agreements with prior to FDA approval. I interpret the sentence to mean “additional” contracts, those waiting for FDA Approval perhaps or those that may have had IPIX-cost related to contract execution, that could now be executed.
It not possible, given public information, to know if testing has already begun. I am confident that multiple site are contracted, perhaps already testing and evaluating outcomes.
No scam stock or gravy train CEO would risk their free ride by placing their primary drug candidate in a binary PH2 event of such short duration and for an illness under such public scrutiny. Let’s face it, Brilacidin’s success or failure in this clinical test cycle will translate into the success or failure of Innovation Pharmaceuticals. IPIX decision makers are no doubt susceptible to confirmation bias but they believe in Brilacidin enough to risk the future of the company on the results of the short-duration PH2 trial. I’ll share the risk along with Leo and fellow longs.
I am long and strong in IPIX. I am an investor not a trader. I believe Brilacidin has value for IBD, antibiotics and OM among other maladies. Kevetrin waits in the wings and if even marginally potent has huge value. But if B fails now, on this stage, IPIX will have suffered a fatal blow.
That’s a nice first post. Thank you. Good luck to us.
One can interpret the last sentence in a couple of ways. As written it implies, to me, that selected sites were already prepared to start. With FDA Approval in hand, ADDITIONAL sites will NOW be added. That perhaps, of the total compliment of desired sites; those which were easier, cheaper, less complicated or previously engaged in relationship with the CRO (one or more of the above conditions, add your own conditions as you see fit), were signed-up while others; more expensive to secure, more complicated to contract or, by their own pre-condition, desirous of FDA trial approval could NOW be secured. The Approval was a hurdle that had to be overcome before investing resources and executing final agreements with a subset of test sites.
I had a feeling you would like the word choice. GLT you and A IPIX Longs.
Will these fireworks be MOMENTOUS?
Thank you for posting the article. The closer we come to putting Brilacidin to the ultimate test the more difficult it becomes to remain patient and calm. The fact that an additional manufacture has identified Brilacidin as a worthy candidate for production proof-of-concept studies (and investment of resources), and, further still, is willing to cite those activities as an example of their preparedness for rapid manufacturing ramp up is encouraging.
GLTALs. Go IPIX. Get the trials underway.